Depressive symptoms in adolescents with early and continuously treated phenylketonuria: Associations with phenylalanine and tyrosine levels

Gene

Volumn 504, Issue 2, 2012, Pages 288-291

  Sharman, Rachael ^a,b   Sullivan, Karen ^b   Young, Ross McD ^b   McGill, Jim ^c  

^a UNIVERSITY OF THE SUNSHINE COAST   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Depression; Phenylalanine; Phenylketonuria; PKU; Tyrosine

Indexed keywords

BIOLOGICAL MARKER; PHENYLALANINE; TYROSINE;

ADOLESCENT; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; DEPRESSION; DIET; DISEASE ASSOCIATION; EXECUTIVE FUNCTION; HUMAN; LONG TERM EXPOSURE; MOOD; PHENYLKETONURIA; PRIORITY JOURNAL; SIBLING;

ADOLESCENT; DEPRESSION; HUMANS; PHENYLALANINE; PHENYLKETONURIAS; TYROSINE;

EID: 84862766659     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.05.007     Document Type: Article

References (26)

1. Antshel K.M., Waisbren S.E. Timing is everything: executive functions in children exposed to elevated levels of phenylalanine. Neuropsychology 2003, 17:458-468.
2. Arnold G.L., Vladutiu C.J., Orlowski C.C., Blakely E.M., DeLuca J. Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria. J. Inherit. Metab. Dis. 2004, 27:137-143.
3. Australian Society for Inborn Errors of Metabolism The PKU Handbook 2005, Human Genetic Society of Australia, Alexandra, Victoria.
4. DeRoche K., Roche M. Twenty-five years of research on neurocognitive outcomes in early treated phenylketonuria: intelligence and executive function. Dev. Neuropsychol. 2008, 33:474-504.
5. Diamond A., Prevor M.B., Callender G., Druin G.P. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr. Soc. Res. Child Dev. 1997, 62:1-208.
6. Gentile J.K., Ten Hoedt A.E., Bosch A. Psychosocial aspects of PKU: Hidden disabilities-a review. Mol. Genet. Metab. 2010, 99(Suppl. 1):64-67.
7. Gioia G.A., Isquith P.K., Guy S.C., Kenworthy L. Behaviour Rating Inventory of Executive Function 2000, Psychological Assessment Resources Inc., Lutz, FL.
8. Grevet E.H., et al. Behavioural effects of acute phenylalanine and tyrosine depletion in healthy male volunteers. J. Psychopharmacol. 2002, 16:51-55.
9. Harvie M.N., Campbell I.T., Howell A., Thatcher N. Acceptability and tolerance of a low tyrosine and phenylalanine diet in patients with advanced cancer-a pilot study. J. Hum. Nutr. Diet. 2002, 15:193-202.
10. Hassan K., Loar R., Anderson B.J., Heptulla R.A. The role of socioeconomic status, depression, quality of life, and glycemic control in type 1 diabetes mellitus. J. Pediatr. 2006, 149:526-531.
11. Huijbregts S.C., de Sonneville L.M., van Spronsen F.J., Licht R., Sergeant J.A. The neuropsychological profile of early and continuously treated phenylketonuria: orienting, vigilance, and maintenance versus manipulation-functions of working memory. Neurosci. Biobehav. Rev. 2002, 26:692-712.
12. Koch R., Moseley K., Yano S., Nelson M., Moats R.A. Large neutral amino acid therapy and phenylketonuria: a promising approach to treatment. Mol. Genet. Metab. 2003, 79:110-113.
13. Kovacs M. Children's Depression Inventory 1992, Multi-Health Systems, North Tonowanda, NY.
14. Leuzzi V., et al. Executive function impairment in early-treated PKU subjects with normal mental development. J. Inherit. Metab. Dis. 2004, 27:115-125.
15. Luciana M., Sullivan J., Nelson C.A. Associations between phenylalanine-to-tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria. Child Dev. 2001, 72:1637-1652.
16. Mahone E.M., et al. Validity of the behaviour rating inventory of executive function in children with ADHD and/or Tourette syndrome. Arch. Clin. Neuropsychol. 2002, 17:643-662.
17. Mangeot S., Armstrong K., Colvin A.N., Yeates K.O., Taylor H.G. Long-term executive function deficits in children with traumatic brain injuries: assessment using the Behaviour Rating Inventory of Executive Function (BRIEF). Child Neuropsychol. 2002, 8:271-284.
18. Sharman R., Sullivan K., Young R., McGill J. Biochemical markers associated with executive function in adolescents with early and continuously treated phenylketonuria. Clin. Genet. 2009, 75:169-174.
19. Sharman R., Sullivan K., Young R., McGill J. A preliminary investigation into the role of the phenylalanine:tyrosine ratio in children with early and continuously treated phenylketonuria: towards identification of "safe" levels. Dev. Neuropsychol. 2010, 35:57-65.
20. Smith I., Knowles J. Behaviour in early treated phenylketonuria: a systematic review. Eur. J. Pediatr. 2000, 159(Suppl. 2):94-95.
21. Ten Hoedt A.E., et al. High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomized, double-blind, placebo controlled crossover trial. J. Inherit. Metab. Dis. 2011, 34:165-171.
22. Tremblay P., Blier P. Catecholaminergic strategies for the treatment of major depression. Curr. Drug Targets. 2006, 7:149-158.
23. Tremblay L.K., Naranjo C.A., Cardenas L., Herrmann N., Busto U.E. Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Arch. Gen. Psychiatry 2002, 59:409-415.
24. Waisbren S.E., White D.A. Screening for cognitive and social-emotional in individuals with PKU: tools for use in the metabolic clinic. Mol. Genet. Metab. 2010, 99(Suppl. 1):96-99.
25. Whittemore R., Kanner S., Singleton S., Hamrin V., Chiu J., Grey M. Correlates of depressive symptoms in adolescents with type 1 diabetes. Pediatr. Diabetes. 2002, 3:135-143.
26. Wierzbicki M. A parent form of the Children's Depression Inventory: reliability and validity in nonclinical populations. J. Clin. Psychol. 1987, 43:390-397.